Hai Tran

Associate Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hai Tran is an Associate Professor at The University of Texas MD Anderson Cancer Center in the United States. His research focuses on lung cancer, particularly on topics such as the role of circulating tumor DNA, immune response in tumor environments, and resistance mechanisms to targeted therapies. Recent publications include studies on the effects of Aurora Kinase A inhibitors and the implications of tumor genomic profiling on clinical outcomes in non-small-cell lung cancer.

Articles (12)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

Stanford University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hai Tran

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas

Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer

Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer

Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC

Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC

Plasma based protein signatures associated with small cell lung cancer

Collaborators (6)

Daniel McGrail

Vincent K. Lam

xiaochao tan

Alexandre Reuben

YASIR ELAMIN

Sonia Patel

Make your next move.